NO872581D0 - Oeket produksjon av antistoffer ved anvendelse av insolubiliserte immunkomplekser. - Google Patents

Oeket produksjon av antistoffer ved anvendelse av insolubiliserte immunkomplekser.

Info

Publication number
NO872581D0
NO872581D0 NO872581A NO872581A NO872581D0 NO 872581 D0 NO872581 D0 NO 872581D0 NO 872581 A NO872581 A NO 872581A NO 872581 A NO872581 A NO 872581A NO 872581 D0 NO872581 D0 NO 872581D0
Authority
NO
Norway
Prior art keywords
immunic
complexs
insolubilized
antibodies
increased production
Prior art date
Application number
NO872581A
Other languages
English (en)
Other versions
NO872581L (no
Inventor
Jr Alton C Morgan
Clive S Woodhouse
Robert F Mcintyre
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Publication of NO872581D0 publication Critical patent/NO872581D0/no
Publication of NO872581L publication Critical patent/NO872581L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO872581A 1986-06-20 1987-06-19 Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser. NO872581L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87682886A 1986-06-20 1986-06-20
US07/024,632 US4879225A (en) 1986-06-20 1987-03-11 Enhanced production of antibodies utilizing insolubilized immune complexes

Publications (2)

Publication Number Publication Date
NO872581D0 true NO872581D0 (no) 1987-06-19
NO872581L NO872581L (no) 1987-12-21

Family

ID=26698676

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872581A NO872581L (no) 1986-06-20 1987-06-19 Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.

Country Status (7)

Country Link
US (1) US4879225A (no)
EP (1) EP0251065A3 (no)
JP (1) JPS63258496A (no)
CN (1) CN87105716A (no)
AU (1) AU615628B2 (no)
DK (1) DK315187A (no)
NO (1) NO872581L (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2220140A (en) * 1988-05-05 1990-01-04 Nat Res Dev Immunogenic complex and its use in vaccination
CA2080835A1 (en) 1990-04-18 1991-10-19 Jan H. Wong A 35kd tumor associated protein antigen and immune complex
US5723115A (en) * 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
CA2098960C (en) * 1992-07-10 2004-11-02 Richard Barner Bio specifically recognizing surfaces on solid supports and method for their preparation
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994016706A1 (en) 1993-01-28 1994-08-04 Neorx Corporation Therapeutic inhibitors of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB9606425D0 (en) * 1996-03-27 1996-06-05 Binding Site Ltd Improvements in and relating to the production of antibodies and test kits incorporating antibodies
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
ES2193240T3 (es) * 1996-05-15 2003-11-01 Altarex Inc Metodo y composicion para reconformar antigenos multi-epitopicos para iniciar una respuesta inmune.
JP2001521503A (ja) 1997-03-31 2001-11-06 ネオルックス コーポレイション 血管平滑筋細胞の治療的阻害物質
AU2610000A (en) 1999-01-12 2000-08-01 Cambridge University Technical Services Limited Compounds and methods to inhibit or augment an inflammatory response
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
JP3600231B1 (ja) * 2003-09-30 2004-12-15 森永製菓株式会社 イムノアッセイ
WO2019199918A1 (en) * 2018-04-11 2019-10-17 Cowan Fred M Compositions and methods for prevention and treatment of immune complex disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400376A (en) * 1979-03-27 1983-08-23 National Research Development Corporation Immunological preparations
IL63220A (en) * 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
US4471058A (en) * 1982-07-26 1984-09-11 Board Of Trustees Operating Michigan State University Method for the detection and/or determination of a polyvalent antigen using at least two different monoclonal antibodies
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
FR2558165B1 (fr) * 1984-01-17 1986-07-04 Anvar Nouveaux conjugues d'oligo-muramylpeptides et compositions biologiques les contenant pour l'activation des macrophages

Also Published As

Publication number Publication date
NO872581L (no) 1987-12-21
EP0251065A3 (en) 1989-08-30
CN87105716A (zh) 1988-06-08
AU7449687A (en) 1987-12-24
JPS63258496A (ja) 1988-10-25
US4879225A (en) 1989-11-07
EP0251065A2 (en) 1988-01-07
AU615628B2 (en) 1991-10-10
DK315187D0 (da) 1987-06-19
DK315187A (da) 1987-12-21

Similar Documents

Publication Publication Date Title
NO872581D0 (no) Oeket produksjon av antistoffer ved anvendelse av insolubiliserte immunkomplekser.
ATE72660T1 (de) Herstellung von zeolith-l.
FI871789A (fi) Anordning foer uppspaerrning av saor.
FI884497A (fi) Menetelmä uusien, aromataasia inhiboivien 4(5)-imidatsolien valmistamiseksi
DE3882852D1 (de) Herstellung von diglyceriden.
DE3577546D1 (de) Herstellungsverfahren von methylmethacrylaten.
TR28392A (tr) Seramik bilesikler yapma metodu.
DE3785603D1 (de) Produktion von epsilon-kaprolaktam.
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
FR2593175B1 (fr) Procede de production de 3-phenyl-4-cyanopyrroles.
DE3789121D1 (de) Entwicklungsverfahren.
TR24874A (tr) POTASYUM SILIKAT CÖZELTILERININ HIDROTERMIK üRETIMINE MAHSUS USUL.
DE3583636D1 (de) Herstellungsverfahren von kaliumhydroxyd.
IT8722894A0 (it) Procedimento di produzione di un polifenilenetere.
FI881866A0 (fi) Perunakuidun valmistusmenetelmä
DE3875281D1 (de) Herstellung von pseudoiononen.
DE3884654D1 (de) Herstellung von chromogenischen Cryptahemispheranden.
DE3885851D1 (de) Modifizierungsverfahren.
TR23494A (tr) Ferrokrom ueretme islemi
NO885200D0 (no) FremgangsmŸte for fremstilling av pro-legemidler.
DE3582003D1 (de) Herstellung von glycolmonoestern.
IT7828258A0 (it) Processo per la produzione di lattulosio.
DE3750736D1 (de) Entformungsverfahren.
DE69019301D1 (de) Herstellungsverfahren von Indolen.
DE3869465D1 (de) Herstellung von 4-pentenoat durch isomerisation.